Table 3.

Ongoing clinical phase III trials, chemotherapy with immune checkpoint inhibitors (ICIs) for cervical cancer.

Title	Study Population	n	Phase	Treatment	Primary Outcomes	Secondary Outcomes	Clinical Trial Code
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination with Platinum-Based Chemotherapy with and Without Bevacizumab as First-Line Treatment of Subjects with Advanced Cervical Cancer (FERMATA) [26]	Advanced cervical cancer	316	III	Paclitaxel + cisplatin (or carboplatin) Bevacizumab BCD-100 (anti-PD-1)	OS	PFS, ORR, DOR	NCT03912415
Efficacy and Safety Study of First-Line Treatment with Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women with Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) [27]	Recurrent or metastatic cervical cancer	600	III	Paclitaxel + cisplatin (or carboplatin) Bevacizumab Pembrolizumab	PFS, OS	ORR, DCR, DOR	NCT03635567
Platinum Chemotherapy Plus Paclitaxel with Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix [28]	Recurrent or metastatic cervical cancer	404	III	Paclitaxel + cisplatin Bevacizumab Atezolizumab	OS	PFS, ORR, DOR, AE	NCT03556839

OS: overall survival rate; PFS: progression-free survival; ORR: objective response rate; DOR: duration of response; DCR: disease control rate; QOL: quality of life; and AE: adverse event.